(Q37357297)

19 August 2017

1 reference

title

PET and PET-CT imaging of gynecological malignancies: present role and future promise (English)

1 reference

19 August 2017

3

Abass Alavi

1 reference

19 August 2017

Sandip Basu

1

1 reference

PubMed ID

19105709

19 August 2017

Geming Li

series ordinal

2

1 reference

19 August 2017

1 January 2009

1 reference

Expert Review of Anticancer Therapy

19 August 2017

1 reference

19 August 2017

9

1 reference

19 August 2017

1

1 reference

19 August 2017

75-96

1 reference

Management of metastatic cervical cancer: review of the literature

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Molecular approaches to cervical cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Staging of carcinoma of the uterine cervix and endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Contribution of whole-body 18FDG PET imaging in the management of cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Posttherapy surveillance monitoring of cervical cancer by FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

FDG-PET in carcinoma of the uterine cervix with endometrial extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

FDG-PET for management of cervical and ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Sequential FDG-PET brachytherapy treatment planning in carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Ovarian cancer. Current outlook on this deadly disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Clinical value of positron emission tomography with FDG for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

(18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

The impact of PET/CT in the management of recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

PET-CT vs. CT alone in ovarian cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

18F-FDG PET in the management of endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

The pharmacology and clinical uses of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

FDG-PET evaluation of vaginal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

PET-CT localizes previously undetectable metastatic lesions in recurrent fallopian tube carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

PET imaging in gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.75

21 January 2018

Identifiers

DOI

10.1586/14737140.9.1.75

1 reference

19 August 2017

1 reference

PubMed ID

19105709